Fluoxetine vs Escitalopram Oxalate — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Serotonin Reuptake Inhibitor

Fluoxetine

Brand: FLUOXETINE

First FDA approval: 1988-02-01

Serotonin Reuptake Inhibitor

Escitalopram Oxalate

Brand: Escitalopram

First FDA approval: 2012-04-03

Lowest NADACAcquisition cost floor across all NDCs

$0.030Per unit

$0.041Per unit

Average NADACAcross all dosage forms and strengths

$0.694Up to $30.42

$0.059Up to $0.139

Generic manufacturersActive ANDA holders — FDA Orange Book

2467 total ANDAs filed

1441 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$148.8MFull year

$245.8MFull year

Part D claims (CY24)Total fills, all strengths

11.3M2.8M beneficiaries

19.2M5.1M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$13Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes24 manufacturers

Yes14 manufacturers